UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for asthma in the United Kingdom. Explore treatment pathways including biologics, inhaled therapies, and novel interventions.
Asthma affects ~5.4 million people in the UK (~8% of the population). It causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing. While most asthma is well-controlled with standard inhalers, ~5-10% of patients have severe asthma that does not respond to conventional treatment. This group accounts for a disproportionate share of asthma attacks, hospital admissions, and asthma deaths.
For severe asthma, biologic therapies have been transformative. These target specific inflammatory pathways: omalizumab (Xolair) targets IgE for allergic asthma, mepolizumab (Nucala) and benralizumab (Fasenra) target IL-5 for eosinophilic asthma, dupilumab (Dupixent) blocks IL-4/IL-13 for T2-high asthma, and tezepelumab (Tezspire) targets TSLP upstream. NICE recommends these for patients with severe eosinophilic or allergic asthma who remain uncontrolled on high-dose inhaled steroids.
Step 1: Short-acting reliever (SABA - salbutamol). Step 2: Low-dose inhaled corticosteroid (ICS). Step 3: ICS + LABA (combination inhaler). Step 4: High-dose ICS + LABA ± LTRA (montelukast). Step 5: Severe asthma - refer to specialist centre for biologic assessment. Maintenance and reliever therapy (MART) using budesonide/formoterol is increasingly preferred.
Active UK asthma trials include: next-generation biologics targeting novel pathways (anti-TSLP, anti-IL-33), once-daily inhaled combinations, oral corticosteroid-sparing strategies, bronchial thermoplasty for severe asthma, digital inhaler monitoring, and precision medicine approaches based on inflammatory phenotyping (T2-high vs T2-low). The NHS has dedicated severe asthma centres across the UK.
Free AI-powered matching - no signup required
Search severe asthma Trials →